Alder BioPharmaceuticals (ALDR) Receives Coverage Optimism Rating of 0.27
Media coverage about Alder BioPharmaceuticals (NASDAQ:ALDR) has been trending positive recently, according to Accern Sentiment. The research group identifies negative and positive news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Alder BioPharmaceuticals earned a daily sentiment score of 0.27 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 46.1464526573111 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the media headlines that may have effected Accern’s rankings:
- DELTA DRONE :Half-yearly report on the liquidity agreement with Louis Capital Markets (finance.yahoo.com)
- Alder BioPharmaceuticals, Inc. (ALDR) Receives Consensus Rating of “Buy” from Analysts (americanbankingnews.com)
- Alder BioPharmaceuticals (ALDR) Lifted to Sell at ValuEngine (americanbankingnews.com)
- What Do Analysts Think About Alder Biopharmaceuticals Inc’s (NASDAQ:ALDR) Earnings Trend? (finance.yahoo.com)
- DELTA DRONE : strengthens its position in Africa and now wholly owns Delta Drone Africa (finance.yahoo.com)
ALDR has been the topic of a number of recent research reports. Royal Bank of Canada initiated coverage on Alder BioPharmaceuticals in a report on Thursday, September 14th. They issued an “outperform” rating and a $17.00 target price on the stock. Canaccord Genuity initiated coverage on Alder BioPharmaceuticals in a report on Thursday, October 26th. They issued a “buy” rating and a $20.00 target price on the stock. Mizuho reissued a “buy” rating and issued a $32.00 target price on shares of Alder BioPharmaceuticals in a report on Friday, September 15th. ValuEngine downgraded Alder BioPharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Wednesday, October 18th. Finally, BidaskClub downgraded Alder BioPharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, December 19th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and eleven have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $27.71.
Alder BioPharmaceuticals (NASDAQ:ALDR) opened at $12.95 on Friday. Alder BioPharmaceuticals has a 12 month low of $8.60 and a 12 month high of $25.45. The company has a market capitalization of $877.50, a PE ratio of -2.42 and a beta of 2.48.
Alder BioPharmaceuticals (NASDAQ:ALDR) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.92) EPS for the quarter, topping the consensus estimate of ($1.21) by $0.29. During the same period in the prior year, the company posted ($0.70) earnings per share. equities analysts predict that Alder BioPharmaceuticals will post -5.14 earnings per share for the current fiscal year.
In other news, insider Mark James Litton sold 16,519 shares of the firm’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $10.80, for a total value of $178,405.20. Following the transaction, the insider now owns 116,451 shares of the company’s stock, valued at $1,257,670.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 10.60% of the stock is owned by company insiders.
Alder BioPharmaceuticals Company Profile
Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.
Receive News & Ratings for Alder BioPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.